SCHEMBL1743327

SCHEMBL1743327

NC(=O)c1ccccc1Oc1cccc2[nH]ncc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 1/20 0.49
PLK4 O00444 1/20 0.46
CHEK1 O14757 1/20 0.46
AURKA O14965 1/20 0.46
DAPK3 O43293 1/20 0.46
MAP4K4 O95819 1/20 0.46
CSF1R P07333 1/20 0.46
RET P07949 1/20 0.46
FGFR1 P11362 1/20 0.46
PDGFRA P16234 1/20 0.46
LTK P29376 1/20 0.46
KDR P35968 1/20 0.46
MAP2K2 P36507 1/20 0.46
FLT3 P36888 1/20 0.46
CSNK1A1 P48729 1/20 0.46
PRKX P51817 1/20 0.46
CDK5 Q00535 1/20 0.46
MAP2K1 Q02750 1/20 0.46
MST1R Q04912 1/20 0.46
PTK2 Q05397 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29360810 0.82 CSF1R (0.56) PLK4CHEK1AURKADAPK3MAP4K4
SCHEMBL1134888 0.82 CSF1R (0.56) PLK4CHEK1AURKADAPK3MAP4K4
SCHEMBL28199257 0.82 NOS1 (0.57) RETNOS1CDK2DRD2DRD4
SCHEMBL31409300 0.78 METAP2 (0.55) PLK4CHEK1AURKADAPK3MAP4K4
SCHEMBL7693879 0.76 CTNNB1 (0.77) CTNNB1IRAK4METAP2PARP1LMNA
SCHEMBL28578209 0.74 KMT2A (0.61) CTNNB1IRAK4LMNACYP3A4HPGD
SCHEMBL1008429 0.74 CTNNB1 (0.48) CTNNB1PLK4CHEK1AURKADAPK3
SCHEMBL2315260 0.73 METAP2 (0.47) NOS1DRD2DRD4DRD3KIT
SCHEMBL1008229 0.72 CTNNB1 (0.56) CTNNB1PLK4CHEK1AURKADAPK3
SCHEMBL27780639 0.72 SLC22A6 (0.47) AURKACSF1RKDRFLT3ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2387559-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES Abbott Laboratories (US) 2011-11-23 EP claimed
EP-2376480-A2 SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES Abbott Laboratories (US) 2011-10-19 EP claimed
WO-2010083442-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBOTT LABORATORIES (US) 2010-07-22 WO claimed
WO-2010065865-A2 BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES ABBOTT LABORATORIES (US) 2010-06-10 WO claimed
EP-2642999-A1 METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS AbbVie Inc. (US) 2013-10-02 EP disclosed
EP-2507229-A1 SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES Abbott Laboratories (US) 2012-10-10 EP disclosed
WO-2012071374-A1 METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS ABBOTT LABORATORIES (US) 2012-05-31 WO disclosed
EP-2376480-A2 SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES Abbott Laboratories (US) 2011-10-19 EP disclosed
WO-2010065865-A2 BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES ABBOTT LABORATORIES (US) 2010-06-10 WO disclosed